| Vol. 14.12 – 29 March, 2022 |
| |
|
|
| MiR-378 amplified osteoarthritis (OA) development via repressing chondrocyte autophagy and by inhibiting bone marrow MSC chondrogenesis, thus indicating miR-378 may be a potential therapeutic target for OA treatments. [Molecular Therapy-Nucleic Acids] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists investigated the therapeutic potential of bevacizumab in angiogenesis during osteosarcoma and the related mechanisms. [Cell Death & Disease] |
|
|
|
| The authors investigated the mechanism of bone marrow MSC-derived exosome using high phosphate stimulated human aortic smooth muscle cells and 5/6 subtotal nephrectomy rat models. [Cell Death & Disease] |
|
|
|
| Investigators showed that CoCl2-treated MSCs possessed activated NF-κB signalling pathways, and its pharmacological inhibition significantly relieved their growth arrest. [Stem Cell Reviews and Reports] |
|
|
|
| Researchers analyzed the formation of the pro-inflammatory cytokines TNFα and IL-6 in lipopolysaccharide (LPS)- or lipoteichoic acid (LTA)-stimulated cells from the dental pulp interface and pulp fibroblasts in the presence of the resin monomer 2-hydroxyethyl methacrylate (HEMA). [Dental Materials] |
|
|
|
| Scientists investigated the decoy receptor osteoprotegerin axis and determined the effect of exendin-4 upon adipose MSC osteogenic differentiation. [Journal of Cellular Biochemistry] |
|
|
|
| The authors investigated the anti-inflammatory effects of MSCs on lipopolysaccharide-stimulated macrophages and the subsequent downregulation of their inflammatory mediators. [Scientific Reports] |
|
|
|
| Scientists directed human Wharton’s jelly-MSCs chondrogenesis using micropattern made of spidroin bioink as opposed to fibronectin that often was used as the gold standard. [Scientific Reports] |
|
|
|
| Investigators reported that in aged human mesenchymal progenitor cells, apolipoprotein E (APOE) accumulation was a driver for cellular senescence. [Nature Aging] |
| |
|
|
| Researchers explored the role of non-coding RNA activated by DNA damage (NORAD) derived from extracellular vesicles of bone MSCs in osteosarcoma. [Laboratory Investigation] |
|
|
|
| Human umbilical cord-derived MSCs were subcutaneously injected into mice with imiquimod-induced psoriasis-like skin inflammation to explore the feasibility of this cellular therapy. [Cell and Tissue Research] |
|
|
|
| Investigators observed tumor formation in NOD SCID mice after a single subcutaneous injection of human umbilical cord-MSCs and the effect of these cells on tumor growth in tumor-bearing mice. [BMC Cancer] |
|
|
|
|
Researchers evaluated the capacity of allogeneic MSCs to induce dental-pulp and apical bone regeneration in a tooth previously endodontically treated. [Journal of Endodontics] |
| | |
|
|
| Scientists summarize the biological effects and mechanisms of action of MSCs, elucidating recent clinical trials phases and findings, and highlighting therapeutic effects of MSCs in several representative diseases [Stem Cell Reviews and Reports] |
|
|
|
| The authors summarize current evidence from in vitro studies, animal models, and their clinical experience, to support stromal cell therapy in multiple clinical indications. [Frontiers in Immunology] |
|
|
|
|
| Neuroplast has enrolled its first patient in a Phase II clinical trial to evaluate efficacy of its transformative Neuro-Cells® treatment that aims to prevent further damage to the central nervous system after sustaining acute traumatic spinal cord injury. [Neuroplast] |
|
|
|
| IMAC Holdings, Inc. announced it has initiated the third and final cohort of its Phase I clinical trial for its investigational compound utilizing umbilical cord-derived allogenic MSCs for the treatment of bradykinesia due to Parkinson’s disease. [IMAC Holdings, Inc. (] |
|
|
|
|
| June 15 – 18, 2022 San Francisco, California, United States |
|
|
|
|
|
| Cancer Research UK Manchester Institute – Manchester, England, United Kingdom |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| Gilead Sciences – Foster City, California, United States |
|
|
|
| University of Barcelona – Barcelona, Spain |
|
|
|
|